CrushSCI.com
83.7平均天数
70.5中位天数
16最短天数
205最长天数
2372025发文量

Paper Review Records

全部论文审稿周期

18 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

70 天

Late acquisition of BCR::ABL1 during clonal evolution of SAMD9- associated MDS with phenotypic shift from AML to B-ALL

作者
Yusuke Nakata; Anna Hiratsuka; Takeshi Yoroidaka; Wakana Takahashi; Itaru Nishikawa; Masataka Sakashita; Shinya Yamada; Hiroki Mizumaki; Akiyo Yoshida; Tatsuya Imi; Hiroyuki Maruyama; Hiroyuki Takamatsu; Kohei Hosokawa; Yasuhito Nannya; Seishi Ogawa; Toshihiro Miyamoto展开收起
作者单位
1. Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; 2. Division of Hematology, Keiju Kanazawa Hospital, Kanazawa, Japan; 3. Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 4. Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan展开收起
PDF源文件 DOI 网页
119 天

Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study

作者
Ryo Koizumi; Shinsuke Takagi; Aya Nishida; Mika Kuno; Rikako Tabata; Otoya Watanabe; Kyosuke Yamaguchi; Kosei Kageyama; Daisuke Kaji; Yuki Taya; Kazuya Ishiwata; Hisashi Yamamoto; Akiko Masuda; Yukako Koike; Hideki Araoka; Yuki Asano-Mori; Go Yamamoto; Atsushi Wake; Shuichi Taniguchi; Naoyuki Uchida展开收起
作者单位
1. Department of Hematology, Toranomon Hospital, Tokyo, Japan; 2. Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan; 3. Okinaka Memorial Institute for Medical Research, Tokyo, Japan; 4. Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan; 5. Department of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan; 6. Center for Cellular Therapy, Toranomon Hospital, Tokyo, Japan; 7. Department of Clinical Laboratory, Toranomon Hospital, Tokyo, Japan展开收起
PDF源文件 DOI 网页
113 天

Gene editing of hematopoietic stem cells: applications and advances

作者
Qiuyang Li; Hongxia Wang; Yuqin He; Genyue Hong; Guoxiu Bao展开收起
作者单位
1. Department of Hematology, Dali Bai Autonomous Prefecture People’s Hospital in Dali, Dali City, China展开收起
PDF源文件 DOI 网页
68 天

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis

作者
Makoto Kashimura; Yuki Fujioka; Yong-Mei Guo; Teruko Takahashi; Keiichi Moriya; Naoto Takahashi展开收起
作者单位
1. Division of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan; 2. Division of Central Laboratory, Akita University Hospital, Akita, Japan; 3. Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan展开收起
PDF源文件 DOI 网页
205 天

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study

作者
Yoshinobu Kanda; Katsuto Takenaka; Tatsu Tanabe; Kazuya Omoto; Kei Kamimura; Kentaro Kudou; Masato Kaneko展开收起
作者单位
1. Division of Hematology, Jichi Medical University, Shimotsuke, Japan; 2. Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University, Matsuyama, Japan; 3. Department of Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan; 4. Yochomachi Clinic, Tokyo, Japan; 5. Takeda Pharmaceutical Company Limited, Osaka, Japan展开收起
PDF源文件 DOI 网页
71 天

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial

作者
Koji Izutsu; Ayumi Fujimoto; Shinya Rai; Dai Maruyama; Ken Ohmachi; Akihiko Yokohama; Kunihiro Tsukasaki; Toshiki Uchida; Junya Kuroda; Ilseung Choi; Michihiro Hidaka; Jun Ando; Takashi Sakamoto; Hisashi Kato; Hironobu Minami; Shinichiro Yoshida; Matsuo Yamamoto; Mireille Gillings; Hiroshi Onogi; Kengo Takeuchi展开收起
作者单位
1. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan; 2. Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; 3. Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; 4. Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Sakai, Japan; 5. Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 6. Department of Hematology and Oncology, Tokai University Hospital, Isehara, Japan; 7. Department of Hematology, Gunma University Hospital, Maebashi, Japan; 8. Department of Hematology, International Medical Center, Saitama Medical University, Hidaka, Japan; 9. Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan; 10. Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan; 11. Department of Hematology and Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan; 12. Department of Hematology, NHO Kumamoto Medical Center, Kumamoto, Japan; 13. Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan; 14. Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 15. Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, Japan; 16. Division of Medical Oncology and Hematology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; 17. Department of Hematology, NHO Nagasaki Medical Center, Omura, Japan; 18. Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan; 19. HUYA BIO International, LLC, San Diego, USA; 20. Huya Japan GK, Tokyo, Japan展开收起
PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。